Products

PROMUS® Everolimus-Eluting Coronary Stent System

Not All Olimus Stents Are Created Equal





The PROMUS Stent System combines a highly deliverable platform with an effective drug and polymer design to provide an optimal olimus, from a partner you trust.

Effective Drug and Polymer Design

  • Everolimus is highly lipophilic1
  • Low drug load2
  • Thin, fluorinated copolymer matrix for controlled drug release
    (100% drug elution in 120 days)3

Exceptional Deliverability

  • Thin 0.0032" cobalt chromium struts for increased flexibility and conformability without compromise to radiopacity2,3
  • Low 0.042" stent profile for enhanced deliverability4




1 Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004;109:2168-2171.
2 PROMUS Stent Directions for Use (DFU).
3 Data on file at Boston Scientific Corporation.
4 Testing of 3.0mm stent completed by Boston Scientific Corporation. Data on file. Bench test results may not necessarily be indicative of clinical performance.



PROMUS Stent is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific Corporation. XIENCE V is a trademark of Abbott Laboratories group of companies.